BioSpace News Archive

Application Based on Objective Response Rate From Phase 2 Trial Evaluating Belzutifan in Patients With Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma New Filing Further Strengthens Merck’s Expanding and Diverse Oncology Portfolio

Data show more than 50 percent of adults with active PsA achieved complete skin clearance (PASI 100) and more than 70 percent achieved at least 20 percent improvement in joint symptoms (ACR 20)

Global Blood Therapeutics, Inc. announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease : one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress.

Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, announced the promotion of Andrew R. Neill to Chief Financial Officer from Vice President of Finance and Corporate Strategy.

Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced recent corporate updates and financial results for the fourth quarter and full year ended December 31, 2020.

Logibec Inc. announced that it has entered into an Asset Purchase Agreement to acquire QoC Health, an Ontario-based company.

Veeva Systems announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that the U.S. Food and Drug Administration has scheduled the pre-approval inspection at the ROLONTIS® manufacturing site in May 2021.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that the FDA issued IND Number 27375 to the Company in connection with its Clinical Trial application